Comparative Pharmacology
Head-to-head clinical analysis: GENTAMICIN versus U GENCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAMICIN versus U GENCIN.
GENTAMICIN vs U-GENCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis; bactericidal against gram-negative aerobes.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
5-7 mg/kg/day IV or IM in divided doses every 8 hours; for serious infections, up to 5 mg/kg/day IV in 3 divided doses.
1-2 mg/kg IV every 8 hours for 7-10 days, targeting peak serum concentration of 6-10 mcg/mL and trough <2 mcg/mL.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 24-48 hours in anuria; adjust dosing based on renal function.
Clinical Note
moderateGentamicin + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Gentamicin."
Clinical Note
moderateGentamicin + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Gentamicin."
Clinical Note
moderateGentamicin + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Gentamicin."
Clinical Note
moderateGentamicin + Acetyldigitoxin
Terminal elimination half-life is 2-3 hours in patients with normal renal function; may prolong to 20-40 hours in end-stage renal disease
Primarily renal (glomerular filtration): 90-95% unchanged in urine over 24 hours; biliary/fecal: <2%.
Primarily renal (glomerular filtration) with 40-70% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%)
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Gentamicin."